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            Abstract  
 
Diabetes is the leading cause of kidney disease worldwide. Screening diabetic patients with 
microalbuminuria is an easy and inexpensive way to detect kidney disease in the early stages. A 
quality improvement project was designed to assist a primary care office in developing a 
standardized process and revising a protocol to increase diabetic kidney screening. The project's 
goal was to align with the Medicare and Medicaid 2019 benchmark of 95% in screening 
individuals with diabetes for chronic kidney disease. The project included revising a screening 
protocol, staff education followed by a questionnaire, and distributing visual kidney screening 
posters. The plan-do-study-act (PDSA) model guided project implementation. Diabetic kidney 
screening was tracked over a 12-week period. Out of 399 eligible patients due for a diabetic 
chronic kidney disease screening, 377 were screened (96%). This project addressed objectives 
related to Healthy People 2020 by increasing diabetic kidney screening, increasing the number of 
individuals aware of having kidney disease, and decreasing the overall burden of kidney disease. 
This project aligns with Triple Aim Initiatives to reduce cost, improve quality of health care and 
health in the diabetic population 
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Section I. Introduction 
Background  
Kidney disease among those with diabetes mellitus is cause for concern; 20% of the 400 
million individuals with diabetes suffer from kidney disease, also known as diabetic nephropathy 
(McGrath & Edi, 2019). Diabetes is the leading cause of kidney disease in the United States, 
accounting for nearly 44% of newly diagnosed cases (National Kidney Foundation [NKF], 
2016). Mortality rates are higher for diabetics with chronic kidney disease compared to those 
without it (Papadakis et al., 2020). In 2017, treating Medicare patients who had a diagnosis of 
chronic kidney disease cost over $84 billion in the United States, and treating people with end-
stage kidney disease (ESKD) cost an additional $36 billion (Center for Disease Control [CDC], 
2020). In 2017, the Medicare spending report revealed that costs were 54% higher for those with 
chronic kidney disease and diabetes versus those with diabetes alone (United States Renal Data 
System [USRDS], 2018a). If detected early during routine screenings, healthcare providers can 
prompt treatment and thwart the disease’s advancement (NKF, 2018). 
Organizational Needs Statement  
The Center for Medicare and Medicaid Services (CMS) recommends a screening metric 
for primary care offices in the United States. The screening metric benchmark for diabetes 
includes testing for nephropathy. The CMS (2019, “Clinical Recommendation Statements” 
section) metric states, “at least once a year, assess urinary albumin (e.g., spot urinary albumin-to-
creatinine ratio) and estimated glomerular filtration rate in patients with Type 1 diabetes for a 
duration of greater than or equal to 5 years and in all patients with Type 2 diabetes". The partner 
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organization for this Doctor of Nursing Practice (DNP) project, a primary care clinic located in 
southwestern North Carolina, currently does not meet this CMS metric.  
  Insurance providers offer reimbursements to healthcare providers based on their 
completion of specific metrics. Screening for diabetic nephropathy counts as a payer contract 
measure. The organization will receive credit for this metric and qualify for reimbursement if a 
urine-microalbumin or urine dipstick for protein is completed. Patient prescriptions for certain 
blood pressure medications such as Angiotensin-converting enzyme (ACE) inhibitor or 
Angiotensin II receptor blockers (ARB) qualify healthcare providers to meet payer contract 
measures as well. Although these prescriptions of medications allow for reimbursement, 
microalbumin urine screening is the only effective way to test diabetic patients for kidney 
disease.  
The goal for the project site is to consistently achieve a 95% completion of the CMS 
metric every quarter in each of their primary care medical clinics. The project partner recognizes 
that some of their clinics within the system are meeting that goal, while others are not. This 
project will focus on one primary care clinic that is not meeting the quality metric. As of March 
31, 2020, this clinic only had a 90% completion rate of screening (K. Meally, personal 
communication, April 3, 2020). The project’s goal is to increase screening of diabetic patients 
for kidney disease at this primary care clinic with the aim of reaching the CMS metric of a 95% 
completion rate. 
Healthy People 2020 have leading health indicators that support the importance of this 
project. A few of these include reducing the proportion of the U.S. population with chronic 
kidney disease and increasing the proportion of persons with diabetes and chronic kidney disease 
who receive the recommended medical evaluation (Healthy People, 2020a). Reducing kidney 
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failure due to diabetes and reducing deaths among persons with chronic kidney disease are 
included in these indicators. This DNP project supports specific Healthy People 2020 goals that 
aim to reduce the burden of chronic kidney disease (CKD) in the United States.   
This project aligns with the Triple Aim by improving the health of the diabetic 
population, improving cost for both the organization and patient, and improving the quality of 
health care. Screening diabetic patients for kidney disease can reduce the burden of 
compounding chronic illness on this already vulnerable population. The mortality rate of diabetic 
patients is linked to the presence and stage of kidney disease. Screening diabetic patients for 
kidney disease can slow the progression of the disease, thereby allowing patients to live a 
healthier, prolonged life (Koyal & Mottl, 2015). 
Problem Statement   
The DNP partner organization inconsistently screens diabetic patients for nephropathy. In 
not doing so, their patients miss out on treatments that could delay the onset of kidney disease. 
Not achieving this component of the CMS metric strains the organization financially. The 
organization not only suffers from significantly fewer reimbursements but bears the far greater 
cost of caring for diabetic patients who may progress to full-stage renal failure without even 
knowing they have the disease.   
Purpose Statement 
The purpose of this project is to increase diabetic nephropathy screenings to 95% at a 
primary medical clinic in southwestern North Carolina to align with the CMS benchmark. A 
standardized urine kidney screening process in diabetic patients will be developed 
collaboratively with all staff members to implement during routine office visits. 
 
 Implementing a Kidney Screening Process                 
	
8	
Section II. Evidence   
Literature Review  
     Databases used for this project included PubMed, The Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), and the University library resources. The initial search 
terms included screening for kidney disease and diabetes. The primary search yielded 47,934 
results. The search was narrowed by using the following MeSH terms: diabetic kidney disease, 
urine-microalbumin, estimated glomerular filtration rate (eGFR), chronic kidney disease (CKD) 
screening tools, primary care, and early detection of CKD. From the search, 12,932 articles were 
identified. With the applied filters of full text, English language, and 2015 to the present, 4,466 
results were found. Some articles focused on the early detection of kidney screening in 
vulnerable populations such as children. Other articles looked specifically at detecting CKD in 
at-risk diabetic groups such as African Americans and hypertensive patients. Although these 
topics are important, they were not specific to this proposed project, which will focus on all 
diabetic patients and were therefore excluded.  
Specific guidelines related to CKD screening in people with diabetes were searched in 
PubMed and CINAHL. Statistical data on current rates of kidney disease, diabetic kidney 
disease, and screening rates of CKD were searched using Google. One guideline from the 
National Kidney Foundation had not changed since 2012. This guideline, although older than 
five years, was included in this paper.  
The hierarchy of quantitative evidence pyramid was used to evaluate the level of 
evidence for each article. The revised Standards for Quality Improvement Reporting Excellence 
(SQUIRE) guidelines were used to assess articles. This method helped identify the level of 
evidence, methods used, study limitations, the aim, and application of findings to this proposed 
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project. After selecting the most relevant articles with a level of evidence of VI or greater from 
all these searches, 22 were used for this project. A literature matrix was used to organize the 
review and synthesis of the articles; this displayed the articles so that level of evidence, purpose, 
limitations, and authors could easily be reviewed and synthesized (See Appendix A). 
Current State of Knowledge  
Worldwide, diabetes is the leading cause of CKD and end-stage kidney disease (Alicic et 
al., 2017; Selby & Taal, 2020). An estimated 37 million Americans have CKD and are at risk for 
kidney failure and cardiovascular disease (NKF, 2020a). Bowe et al. (2018) found that between 
2002 and 2016, the rates of CKD increased in all U.S states, with the most dramatic increase 
seen in the southern U.S. CKD is a clinical syndrome characterized by persistent albuminuria 
and a progressive decline of renal function and can be tested for by checking urinary albumin 
levels (Selby & Taal, 2020).  
Screening for kidney disease is cost-effective and straightforward. The American 
Diabetes Association’s (ADA) clinical screening recommendation is for a once-a-year diabetic 
urinary albumin and estimated eGFR screening for Type 1 diabetes with a duration of over five 
years and in all patients with Type 2 diabetes (T2D) (ADA, 2019). The National Kidney 
Foundation (NKF) also recommends and advocates for screening diabetics for CKD by urinary 
albumin and eGFR (NKF, 2012). The American Association of Clinical Endocrinologists and the 
American College of Endocrinology agrees with these recommendations and suggests similar 
guidelines. They recommend annual screening of urine albumin excretion rate and eGFR 
beginning five years after diagnosis in patients with Type 1 diabetes or at diagnosis in patients 
with Type 2 diabetes but suggests this starts after age 30 (Electronic Clinical Quality 
Improvement, 2018).  
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Healthy People 2020 (2020b) has identified screening for diabetes a priority. The goal is 
to reduce new CKD cases and associated complications, including disability, death, and 
economic costs in 2020. Healthy People 2020 reported that only 33.6% of Medicare beneficiaries 
with diabetes had annual urinary micro-albumin measured in 2007. The target is for a 10% 
increase in 2020 and for 37% of people to be screened. The United States Renal Data System 
reported similar results on the screening rates of CKD in 2016. They found after reviewing data-
claims in diabetic Medicare patients that screening for urine albumin did not happen in half of 
these patients. Completion of urine screenings were only 41.8% on these diabetic patients 
(USRDS, 2018b.) 
Research evidence demonstrates a correlation between diabetes and CKD and the 
inconsistency of CKD screening. Xu, Min et al. (2016) explored the causal association between 
T2D and CKD in Shanghai, China. Utilizing Mendelian Randomization (MR) analysis, Xu, Min 
et al. (2016) looked at 11,502 participants to explore genetic links. The results show a strong link 
between the genetic loci that cause insulin resistance, eGFR, and urinary albumin-to-creatinine 
ratio (UACR). This study concluded that there is a causal relationship between diabetes and 
CKD.  
In a cross-sectional study done at Jimma University Medical Center, data on 9772 
hypertensive and diabetic patients were collected and reviewed to look for predictors of CKD. 
Using multivariate logistic regression, independent predictors for chronic kidney disease include 
ACE nonusers, poor knowledge of CKD, fasting blood sugar over 150 mg/dl, and uncontrolled 
blood pressure of 140/90mmHG or above. The study found that 26% of the patients who had 
elevated blood sugar and low levels of awareness regarding kidney disease had CKD (Kumela et 
al., 2019). These results show another example of the link between hyperglycemia and CKD. 
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Another study, conducted in 2016, known as the See Kidney Disease (SeeKD), aimed to 
determine the prevalence of unrecognized CKD. This project was done in Canada and screened 
6,329 participants from 2011 to 2014. Of the participants screened, 5,194 had at least one risk 
factor for CKD, including diabetes. After screening, 940 participants (18.8%) had unrecognized 
CKD (Galbraith et al., 2016). This study supports the findings that CKD is prevalent in high-risk 
groups and that without screening, it will go undetected. 
The NKF (2020a) published a report that assessed the adequacy of screening individuals 
for CKD. Using LabCorp data facilities, 28,483,459 at-risk patient's charges were reviewed 
between November 2011 and September 2019.  International Classification of Disease (ICD)- 9 
and ICD-10 codes were used to determine the at-risk persons.  At-risk persons had either an 
ICD-9 or ICD-10 code for diabetes, hypertension, or both. The study defined the adequacy of 
CKD screening when both eGFR and UACR had been ordered. Upon review of the data, only 
22% of at-risk individuals had an adequate screening for CKD (NKF, 2020a). This study shows a 
significant need for additional CKD screening. 
Krause et al. (2018) reviewed national claims for 28,348,363 persons. The standard 
Healthcare Effectiveness Data and Information Set (HEDIS) is used by health plans to measure 
and report on quality and performance. HEDIS was used to determine the rate of kidney 
screening. They found that screening for micro-albuminuria is overstated. This is due in part to 
when the National Committee of Quality Assurance (NCQA) expanded their criteria in 2007 for 
satisfying annual screening for diabetic patients to include a step 3. Step 3 includes the utilization 
of an ACE or ARBs. With the presence of a prescription for an ACE inhibitors or ARB, 
satisfaction of the quality-indicator is achieved. However, only 1% of the persons satisfying step 
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3 had evidence of a micro-albuminuria test. Although the quality indicator for screening kidney 
disease may appear satisfied, a spot urine albumin is missing.   
The need to screen diabetic patients for kidney disease is undisputed. Health 
organizations have provided clear evidence-based guidelines that agree with one another in the 
method of screenings. Many institutions and studies have found gaps in the completion of CKD 
screenings, and improvements are needed.  
Current Approaches  
The measurement of eGFR & urinary albumin determines the presence and level of CKD 
(Cockwell & Fisher, 2020). The Center for Medicare and Medicaid Service (CMS) screening 
metric is to “assess once a year a urinary albumin and eGFR rate in patients with diabetes for a 
duration of greater than or equal to 5 years and in all patients with type 2 diabetes (CMS, 2019, 
“Clinical Recommendation Statements” section). This metric originates from the ADA kidney 
screening guidelines (ADA, 2019). The ADA’s gold standard for detecting micro-albumin is a 
timed 24-hour collection of urine; however, this method of screening is time-consuming (NKF 
2020b). The ADA (2019) and NKF (2020b) advise using a spot UACR as a CKD indicator due 
to its reliability and proficiency instead of a 24-hour collection of urine.  
Although micro UACR is a widely accepted routine screening for nephropathy in diabetic 
patients, there are other suggested screenings found in the literature. Wasung et al. (2015) 
summarize research on new biomarkers available for early identification of kidney disease. They 
state that elevation of certain enzymes are present far before urine albumin is. For example, N-
acetyl-β-D-glycosaminidase (NAG) is found to correlate with the direct elevation of serum ACE. 
Serum ACE is a direct indicator of early kidney damage & NAG is elevated before there is an 
elevation of urine albumin in diabetic groups. Although this marker is reliable, it is not cost-
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effective or available to test for in primary care, and more research is needed (Wasung et al., 
2015).  
 ElSharkawy et al. (2016), Salvador Madero (2015), and Rysz et al. (2017) explored in 
their literature reviews the use of old and new biomarkers to identify early CKD. Salvador 
Madero (2015) & Rysz et al. (2017) found that biomarkers are superior to spot UACR in earlier 
detection of CKD. However, Elsharkawy et al. (2016) found that the biomarker for kidney injury 
(KIM1) was not any more effective at screening for CKD than UACR. Although these 
biomarkers appear promising, Rysz et al. (2017) and Salvador Madero (2015) agree more 
research is needed to determine the biomarker’s cost-effectiveness and pathogenesis in people 
with T2D. Due to the small amount of research done and no examples of NAG or biomarkers 
being ordered in primary care, these alternative screenings for CKD were not further 
investigated.  
The proposed DNP project site abides to the CMS diabetic kidney screening metric but 
has not achieved full compliance with this diabetic screening metric. The clinic has the lab and 
equipment to run spot urines to test UACR on site. Completion of this in their diabetic 
population qualifies them for certain reimbursements. However, even with clear clinical 
guidelines and the literature supporting the relationship between diabetes and CKD, the 
screening is often overlooked. In collaboration with the project site partner, a decision was 
agreed on to develop an efficient, standardized process on UACR screening for all diabetic 
patients. This will include refining the existing protocol, educating the staff, educating the staff, 
and working with the quality metric team.   
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Evidence to Support the Intervention 
Chen et al. (2019) conducted a systematic review of 998 articles that focused on the 
diagnosis, evaluation, and management of CKD in the primary care setting. It was concluded that 
since CKD patients are mostly asymptomatic, screening early in detecting the disease is vital. 
Most at-risk patients rely solely on a primary care physician to screen for, diagnose and start 
initial treatments for CKD. These patients typically do not see nephrologists until they have a 
confirmed diagnosis of CKD, and their treatments are past the point of primary care 
management. Screening for CKD must be a priority in primary care so that patients can get the 
care they need.  
In the literature, screening diabetics for CKD with a spot UACR is just as effective as 
screening them with a 24-hour micro-albuminuria (Duru et al., 2018; Karar et al., 2015; McGrath 
& Edi, 2019). Micro-albuminuria is one of the first clinical indicators of kidney disease and is 
considered the primary marker for screening CKD (Chen et al., 2019; McGrath & Edi, 2019).  A 
retrospective study performed between March 2013 and June 2014 by the Department of 
Pathology at King Khalid University Hospital reports similar findings (Hasanato, 2016). One 
hundred and twenty-two patients with T2D were given both a 24-hour urine test and a spot 
UACR test. The study concluded that the performance of UACR was comparable to the 24-hour 
urine albumin assay in excluding renal damage (Hasanato, 2016).  
Another study conducted at Aga Khan University screened 1,280 T2D patients for micro-
albuminuria (Ahmad, 2017). The researchers diagnosed 31.56% (404) of these T2D patients with 
early diabetic nephropathy by utilizing micro-albuminuria screening. They found that micro-
albuminuria was the earliest sign of kidney disease and should be utilized as the first CKD 
screening tool. 
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Deem (2020) conducted a quality improvement initiative for increasing screening for 
diabetic CKD. She implemented three interventions that included an educational meeting, an 
electronic component in the EMR, and practice aids that contained information about protocol 
screening. In her project evaluation, she found that adherence to the ADA screening guideline 
had increased and that staff knowledge regarding CKD screening had improved. This supports 
the importance of utilizing education and protocols in quality improvement projects. 
  Although a streamlined process and protocol may be in place for ordering UACR, if the 
staff is unaware, it will not be used. A qualitative study done in Australia sought to identify the 
barriers and facilitators to CKD screening practices in primary care offices (Sinclair et al., 2017).  
An eight‐item questionnaire guided by the Theory of Planned Behavior was administered to a 
convenience sample of 26 nurses. The results showed that although opinions were high on the 
importance of screening, there was also a strong consensus that there is not enough time or 
awareness of the need to screen for CKD. This belief was especially true when there were 
multiple medical concerns for the patient and not enough information about who needed CKD 
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Evidence-Based Practice Framework  
The operational framework that guided this quality improvement project was the Plan-
Do-Study-Act (PDSA) cycle. In the 1920s, a prominent statistician, Walter A. Shewhart, created 
a model of change consisting of the stages Plan-Do-See (Butts & Rich, 2018). He found that 
more emphasis needed to be on the process of change and less on the product. W. Edwards 
Deming integrated Shewhart’s original work in his book “The New Economics for Industry, 
Government, and Education” to create the PDSA cycle, previously known as the Plan-Do-
Check-Act (Deming, W. Edwards 1900-1993 (William Edwards), 2000). Deming held steady to 
the belief that regarding process changes, “best effort and hard work not guarded by new 
knowledge, only dig deeper the pit we are in” (Deming, W. Edwards 1900-1993 (William 
Edwards), 2000) p. 18). The PDSA cycle was a new framework for change based on the idea of 
continuous movement and is often used in quality improvement to carry out ongoing processes. 
The purpose of PDSA is to effect change quickly, and due to this, it is often referred to as the 
rapid improvement process (Butts & Rich, 2018).  
There are four distinct progressive steps in this framework model. In the planning phase, 
change aimed at improvement is identified. In this phase, information is gathered, objectives are 
defined, data collected, and a plan developed (Crowfoot & Prasad, 2017). Shah-Kan et al. (2019) 
used the PDSA cycle in a quality improvement project to increase bone density screening (BDS) 
in patients with irritable bowel disease (IBD). In their “plan” phase, they identified through a 
retrospective review that only 10.8% of patients with IBD in their practice were adequately 
undergoing bone mineral density (BMD) screening (Shah-Kan et al., 2019). They then defined 
their outcomes, developed their process of change, and created a plan for evaluating the change.                    
In the “Do” phase of PDSA, the idea is carried out, observations documented, and data collected 
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(Crowfoot & Prasad, 2017). Shah-Kan et al. (2019) started implementing their project by 
educating the providers and placing flyers around the office. Throughout the “Do” phase, data 
was collected on the increasing numbers of patients getting screened for BMD. The third stage of 
the PDSA is “Study,” in this phase, data is analyzed, results compared to predictions, and 
progress summarized (Crowfoot & Prasad, 2017). Sha-Kan et al. (2019) saw minimal 
improvement in their goal with solely educating the providers, so in the study phase, they looked 
at opportunities to develop their project by adding an EMR alert. The final stage is to “Act”. In 
this phase, the changes that need to be made are identified for the next cycle of PDSA (Crowfoot 
& Prasad, 2017). Ultimately Sha-Kan et al. (2019) saw an improvement in BMD screening for 
IBD patients after implementing five cycles of PDSA.  
Willison et al. (2016) conducted a quality improvement project utilizing the PDSA 
model. The model was used to identify, implement, and improve screening for UACR and to 
reduce waste from excess testing of more than one UACR a year. Using PDSA, Willison et al. 
(2016) were able to narrow their project to focus on a specific goal. The team went through 
seven different PDSA cycles. Although both project goals were unable to be met, Willison et al. 
(2016) were able to successfully improve patient awareness and increase the number of urines 
brought back to the lab and tested for UACR. They utilized and created an educational leaflet 
and then used the PDSA cycles to make changes to increase the process of their implementation.  
The plan was able to adjust from the original project plan and build on itself by continuing 
through the cycles. 
 The PDSA was utilized in this DNP project, starting with the "Plan" phase. In this phase, 
assessment of the utilization of the current kidney screening protocol for diabetic patients 
occurred. The protocol was changed as needed with input from providers, staff, and 
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administration. The formation of processes and reminders for completing kidney screenings 
during office visits for diabetic patients were developed. Education of the staff regarding the 
updated protocol, the importance of screening diabetics, and the procedure took place in the 
planning phase. In the "Do" phase, the initial implementation of the updated protocol began. 
During this phase, a reminder prompted the ordering of kidney screenings, and the rate of 
completion of kidney screenings was tracked.  During the "Study" phase, an assessment of 
outcomes occurred. Gaps of the new process underwent revisions, strengths were made evident, 
and preparations for the next phase were developed.  
Ethical Consideration & Protection of Human Subjects  
 The target audience for this project was medical assistances and providers who provide 
care to diabetic patients in the primary care clinic. They were educated on the project plan and 
implementation. Type 1 and Type 2 diabetic adults over 18 years of age benefited from the 
interventions. 
 The project’s aim was to implement a standard of care that had no identified risk to the 
population involved. A staff member at the project site provided the patient data for the project 
and sent it to the project lead via a secure email. The information was transferred to excel on the 
project lead’s personal computer, which remained password protected. No personal identifiable 
information was collected, and all information gathered was protected and stored in a double-
locked location. 
The medical center where the project was implemented had a formal internal review 
board (IRB) process for project approval. The project’s site requires non-employee to partner 
with a system employee to co-lead projects within their organization. For this project, the 
project's site champion assisted in completing the formal IRB process.  
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The first step in the project's approval included completing the organization's Quality 
Improvement Project summary form. The form asks specific questions related to the project's 
aim, data collection strategy, evaluation process, and the evidence to support the project. The 
DNP project lead, in partnership with the project site champion, completed the form for 
submission. Prior to submission, the project lead completed human research modules training 
through the Collaborative IRB Training Initiative program. Additionally, data management, 
integrity, security module, and quality improvement modules were required by the organization 
of which only the project site champion completed.  
Discussions occurred between the project lead and faculty about the university review 
process. The first step for the university review process was to complete questions related to the 
project's purpose and provide information about the project's content. The second stage was to 
complete and submit the Quality Improvement Program Evaluation Self Certification assessment 
for faculty approval. Once faculty approved, the assessment was submitted via a Qualtrics survey 
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Section III. Project Design  
Project Site and Population   
This project site is a primary care clinic located in Charlotte, North Carolina. The clinic is 
affiliated with a not-for-profit, self-supporting healthcare system and serves adult patients from 
the surrounding urban areas. The clinic accepts most commercial insurance as well as Medicare 
and Medicaid. 
 A barrier encountered in this project process was obtaining formal approval from the 
project site. This was due to the site's lack of understanding regarding the health system’s 
approval process around nonemployees conducting projects. With collaboration from the 
project's site champion and lead physician, the project plan was defined and approved by the 
health system. Another barrier was implementing during a pandemic. This limited group 
interactions and some aspects of the project education had to be converted to a virtual format.   
Description of the Setting 
The setting for this project took place exclusively at the site's primary care clinic. The 
conference room and the physician's offices were utilized for the site visits. Laminated sheets 
were displayed in patient exam rooms and staff areas. The site has its own laboratory where 
patients in this project had their urine tested for microalbumin. The site utilizes electronic 
medical records (EMR) and shares information directly through their computer systems. All the 
patient information collected for the project came from the EMR.  
 Description of the Population 
The practice has four physicians, one physician assistant, one nurse practitioner, and 
eight medical assistances. Inclusion criteria for participation in the educational sessions were all 
staff holding a medical license and having direct contact with patients. The patient populations 
 Implementing a Kidney Screening Process                 
	
21	
that benefitted from this project were Type 1 and Type 2 diabetics over the age of 18. No 
personal identifiable information was collected on these patients.  
Project Team 
The project team members included the project lead, the nurse manager, the medical 
director or lead physician, the head of quality metrics, and the licensed staff. The project lead 
was responsible for the project's planning, implementation, tracking the project outcomes, and 
making necessary changes to meet the project’s goals. The nurse manager was the site champion 
and served as a co-leader for the project. The project site champion assisted with the 
organization’s institutional review board (IRB) process, educational sessions, and organizing 
implementation dates. The lead physician provided approval and support to engage staff in the 
project and reviewed the educational PowerPoint, and project tools. The leader of quality metrics 
and a member of her staff provided crucial information about the current protocol, offered 
clarifications, and were responsible for extracting and relaying data to the project lead. The 
licensed staff was an essential part of this project team. Since ordering micro-albumin for 
diabetic patients comes first from them, the staff provided feedback on needed project changes 
during the process review. The staff members were also involved in discussions regarding the 
processes that were working and what needed to be changed. They provided meaningful 
suggestions and helped guide the content that was reviewed during each site visit. 
Project Goals and Outcome Measures 
The purpose of this quality improvement project was to increase the screening of kidney 
disease in diabetic patients to achieve the project site’s benchmark and improve the care of 
diabetic patients. The goals were for providers and staff to order micro-albuminuria screenings, 
patients to complete the screening, and the benchmark of 95% to be met. The outcome measures 
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tracked were the number of patients who were eligible for CKD screening, those who qualified 
and received CKD screening, and the total percentage of CKD screenings. 
Description of the Methods and Measurement 
  The first step was planning and revising the diabetic kidney screening protocol and 
creating education for providers and staff. The primary content for the educational session 
included information on the project site’s policy, the updated protocol, and procedures on 
nephrology screening. The current policy and procedure was lengthy and could be confusing. A 
diabetic nephropathy screening protocol was updated using key points from the current policy 
and procedure (See Appendix B). A PowerPoint was created for the virtual educational sessions. 
This included current guidelines, the updated protocol, the need for nephropathy screening, and 
the gaps in the current screening practice. The project site champion and the lead physician 
reviewed, provided feedback, and approved the content for the presentation. 
To assess the staff completion of the virtual educational session, a post diabetic 
nephrology knowledge questionnaire was administered. Permission to use the questionnaire was 
obtained from Dr. Deem (See Appendix C). The six-item questionnaire is based on the ADA 
guidelines on micro-albuminuria screening (See Appendix D). The questionnaire was attached at 
the end of the educational voiced-over presentation, and the participants were directed to click on 
the link and complete the quiz.  
Another method for implementation includes key visual reminders that were created and 
placed in the exam rooms. These laminated sheets alerted staff to order a micro-albuminuria on 
diabetic patients as needed (See Appendix E).  These sheets included relevant ICD 10 codes that 
are commonly linked to micro-albuminuria screening.   
 Implementing a Kidney Screening Process                 
	
23	
The PDSA model was used as an additional implementation tool to evaluate the project's 
process and success. There was an initial PDSA cycle conducted at the start of the project and 
then every four weeks during implementation with a total of four cycles. The data collected was 
evaluated during each PDSA cycle to determine if the educational sessions, protocol, and visual 
reminders effectively increased the screening rates of kidney disease in diabetics. Informal staff 
interviews were conducted in small groups and individually. These interviews were used to 
obtain feedback regarding the protocol and to guide revisions.  
Discussion of the Data Collection Process   
 Data was collected from the EMR with assistance from the site's quality metric manager 
and team member, who were in charge of data extraction. Data collected included: the number of 
diabetic patients who were eligible for CKD screening, the number of patients who received 
CKD screening, and the percentage of urine micro-albumin screenings completed. The data was 
collected using a tool created by the project lead (See Appendix F). The tool also includes a 
section to track if the 95% benchmark had been met during implementation. The data was 
entered into excel for analysis using descriptive statistics and displayed in a bar graph that 
trended against the benchmark of 95%.  
The post questionnaire responses were entered on an excel spreadsheet for data analysis 
and compared to the total number of staff eligible to participate. Only the project lead had access 




 Implementing a Kidney Screening Process                 
	
24	
Implementation Plan  
Implementation began the second week of August 2020. The project lead visited the site 
on August 10 and introduced the project to the staff. Following the initial site visit, a PowerPoint 
presentation was sent electronically to the staff. 
Data was collected biweekly, reviewed, and changes were made utilizing PDSA. Times 
were scheduled with the site champion for the project lead to come to the project site and meet 
with staff members. During these site visits, questions were answered, data was reviewed with 
staff, and further education was provided. During week eight of implementation, laminated 
sheets were distributed and displayed in exam rooms and staff areas.  
Timeline		
The project was implemented over a three-month period beginning in August 2020.  
Following the PowerPoint presentation, data were evaluated biweekly with monthly PDSA cycle 
reviews. The last data collection period and completion date of this project was November 16, 
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Section IV. Results and Findings 
Results  
The project had several goals, including reaching the organization’s benchmark for 
diabetic kidney screening, increasing awareness of the staff on the need to screen for 
nephropathy in diabetic patients, and creating an efficient means of ordering the screenings that 
would be easily adapted into the office workflow. During implementation, quantitative data 
collected included the following: number of patients eligible for micro-albuminuria screening, 
those who were screened for kidney disease, the total percent of those who were screened 
biweekly, the number of clinical staff invited to view the project education, and the number of 
those who viewed the educational session for the project (see Appendix H, Appendix I, and 
Appendix J for displayed findings). 
 Education of the staff was done via a virtual PowerPoint presentation with a post-
evaluation quiz attached. Completion rates of the educational session by the staff were slightly 
over 85%. Of the 14 clinical staff invited to participate in the education, 12 viewed the materials 
(See Appendix H). The post-evaluation quiz was distributed to the clinical staff who participated 
in the education. Of the 12 participants who completed the quiz, 10 (83%) accurately answered 
all six questions. 
There were a total of 399 eligible patients who were seen during the implementation 
period, and 377 (96%) of those were screened for kidney disease (See Appendix J). However, the 
project's goal was to achieve the diabetic nephropathy screening benchmark of 95% biweekly, 
not just in total over the 12 weeks. There was one bi-weekly period where the benchmark goal of 
95% was not met.	During weeks five and six, 70 patients were due for a microalbuminuria 
screen, but only 66 (94.3%) had the screening completed (See Appendix I).  
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 There was a large influx of patients to the clinic in weeks five and six compared to weeks 
one through four. The increase in patients was due to several providers, who saw patients virtual 
during the beginning of implementation, returning to the clinic to see in-person visits. There 
were 70 patients seen in weeks five and six compared to the 43 patients seen in weeks one and 
two and 59 seen in weeks three and four. In weeks seven and eight, there were fewer patients 
(55) seen, and in the last four weeks, the patient numbers increased to 88 and 76, respectively.  
Discussion of Major Findings 
 The PDSA cycle review was conducted to evaluate the project’s process biweekly and 
make changes as needed. A total of four PDSA cycles were completed. During each PDSA 
cycle, the project lead visited the site and met with staff members. During the first PDSA review, 
it was evident that very few staff members had viewed the PowerPoint presentation and 
completed the quiz. At the following visit, donuts were provided to incentivize staff to complete 
the educations. After this visit, the participation increased from 10% to 84% (see Appendix H).   
Prior to the project, the site had been below the 95% goal and consistently meeting the 
goal at around 90%. During implementation, the first and second biweekly screenings, 
nephropathy screenings were above the goal at 97.7 % and 96.6%, respectively (See Appendix 
I). However, during weeks five and six, kidney screenings decreased to 94.3%. There was an 
increase in the nephropathy screening over the last six weeks; the nephropathy goal was met by 
96.4%, 96.5%, and 97.4%, respectively (See Appendix I).           
With a decrease in the goal during weeks five and six, further review was conducted to 
identify the specific patients who had not had a microalbuminuria done. It was identified that 
these patients were under the care of one provider who was consistently missing the screening. 
After further investigation and conversations with the provider and staff, it was determined that 
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the microalbuminuria order was not being entered on every patient encounter. In addition, 
patients unknowingly were leaving the office after their visit without going to the lab, even with 
an active microalbuminuria order. After collaborating with the provider’s Medical Assistant 
(MA), the provider decided that she would alert each patient to check back with her prior to 
leaving the office to see if they needed to have lab work done. Education took place with her, 
including the importance of ordering the microalbuminuria and showing her the EMR alert for 
diabetic kidney screening.  
During the second PDSA cycle review, it was identified during the site visit and 
discussions with staff that the busier the clinical pods were, the more likely staff were to miss a 
screening or forget to direct a patient to the lab even if the screening was ordered. Another 
finding identified in discussions with the staff was that although the EMR has a built-in alert that 
flags patients due for a diabetic kidney screening, staff were often unaware of this alert, how to 
locate it or what it meant. A shortcut to check the status of a diabetic patient’s kidney screening 
in the EMR was identified as an area that some staff needed help locating. Follow-up education 
was provided to the staff on using the EMR technology and identifying patients who were due 
for screening. Staff demonstrated competencies on a return demonstration in looking up and 
ordering needed diabetic kidney screenings on diabetic patients utilizing the EMR tool.  
After the third PDSA cycle review, it was identified that the staff might benefit by having 
a visual tool to remind them to send patients to the clinic.  A simple and easy tool in the form of 
a poster was created to help remind staff to order screenings (See Appendix E). Laminate posters 
were posted in each pod and in several exam rooms during week eight of implementation. These 
posters listed several vital facts related to the importance of screening and identified ICD 10 
codes that can be used for billing the screenings. After the posters were distributed, staff 
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members provided feedback to the project lead on how the posters triggered them to order a 
screening.           
Implementation of a standardized process in diabetic nephrology screening led to an 
improvement in screening diabetic patients for kidney diseases within the organization. By 
increasing staff awareness of the built-in EMR alert and the importance of ordering 
microalbuminuria screening and placing visual reminders, the project site achieved the 
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Section V. Interpretation and Implications   
Cost Benefit Analysis 
This project was time-intensive but financially inexpensive. The financial costs of this 
project were limited to the laminated sheets and the incentives for staff with an estimated total 
cost of $45 (See Appendix K). However, there were significant time commitments in creating the 
visuals, PowerPoint, incorporating the quiz into electronic format, staff education, and one-on-
one meetings with staff. Involving staff over the project’s implementation and engaging them in 
education to ultimately change the way they practice and manage diabetic patients was time-
intensive. Although the project site has a quality metrics department that assists staff in 
achieving certain goals, they work with multiple offices and have limited time to meet with staff. 
A project similar to this would involve additional time for the quality metric staff to manage.    
This project had several benefits for the organization. First and foremost, increasing early 
kidney screenings for diabetics is an essential health maintenance measure to care for the project 
site’s diabetic patient population. A standardized process in ordering diabetic kidney screenings 
increases screenings and can prevent new kidney disease cases thru early identification. Ordering 
early diabetic kidney screenings is inexpensive, and by detecting kidney disease in the early 
stages, healthcare costs can be reduced. As a result of the increased morbidity and mortality 
associated with diabetic nephropathy, those with kidney disease have a high annual healthcare 
cost ranging from $8000 to $43,000 (Zhou et al., 2017).  
This project supported the organization in achieving one of its quality metrics through the 
creation of workflow efficiency in diabetic nephropathy screening that increased 
reimbursements. Insurance companies have created contracts with the organization based on 
benchmarks and a chosen set of quality metrics of which nephropathy monitoring is one. By the 
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organization meeting the Center of Medicare and Medicaid (CMS) benchmark of over 95%, they 
qualify for certain financial reimbursements through payer contract measures.  
Due to the pandemic, many patients had virtual visits and were unable to have lab visits 
done. These patients were not included in the first few weeks of data collection; however, 
midway through the project's implementation, the number of patients that needed to be screened 
greatly increased due to the return of all visits in person. In weeks five and six, when the 
screening was at it is lowest, a larger number of patients were seen in the office and identified as 
eligible for screenings compared to previous weeks. 	
	This project's overall findings demonstrated a positive increase in diabetic screening. 
Screening compliance consistently increased throughout this project, with only a slight deviation 
from the goal. This increase in screening helped the organization qualify for financial 
reimbursements and served to prevent long-term healthcare cost by early identification of kidney 
disease. 
Resource Management  
The organization has a quality metric leader and team that extracts data and can review 
detailed reports to identify which patients missed the screenings and link them to providers/staff 
and circumstances. This is a phenomenal resource provided by the project site. Another resource 
available is a built-in electronic medical record (EMR) alert to remind staff to order nephropathy 
screenings. There is a 24-hour information technology (IT) support staff that manages alerts and 
can be contacted if there are EMR questions or concerns. The project site has its own lab and lab 
technicians that provide assistance with order completions and serves as a major asset to the 
clinical team. All these resources provided support to the project’s improvement of nephropathy 
screenings compliance. 
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 Many of the medical assistances did not have an awareness of who was responsible for 
tracking metrics and why these metrics were important. With education from the quality metric 
team, all clinical staff would have a clear understanding of how metrics are obtained, who 
reviews them, and the importance of achieving the metrics for the project site and patients 
receiving the screening.  
One resource that would benefit the project site would be providing an incentive to the 
non-provider staff members for ordering the micro-albumin screenings. For example, the 
providers receive a direct financial kickback for meeting specific goals, including micro-albumin 
screenings. The staff members who are also responsible and encouraged to order the tests do not 
have any incentives for achieving the goals. Providing a tangible reward such as a team member 
apparel item each month for the staff who has the highest rate of ordering micro-albuminuria on 
diabetic patients who are due may encourage staff to continue screening at high rates.  
Implications of the Findings  
The interventions, organizational resources, and staff participation in this project 
contributed to an improvement in diabetic kidney screenings compliance. With 86% of staff 
participation in the educational sessions and high quiz scores at the beginning of the project, staff 
involvement seemed to contribute to the success of this project. An increase in kidney screenings 
was clearly evident throughout the project implementation period. The cost of educating and 
increasing kidney screenings is relatively low compared to the many compounding costs of 
kidney disease both in the early and end stages. Identifying patients at risk early for kidney 
disease through routine screening can combat further complications associated with the disease. 
The cost to care for a patient with a pre-kidney illness is much less compared to those with 
kidney disease. According to Golestaneh et al. (2017), the mean annualized costs increase 
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exponentially with kidney disease, from $7537 (no CKD) to $76,969 in the commercial group 
and $8091 to $46,178 in the Medicare group. These high costs add to kidney disease's financial 
burden on the health care system. 
During site visits by the project lead, ongoing conversations with staff strengthened the 
knowledge of the importance of screening and the screening process. Over the twelve-week 
period, continual improvement in screening compliance was noted. The project’s site staff 
appeared confident by the end of the project on how to screen and how to identify diabetic 
patients who need a kidney screen. The updated protocol that addresses screening and the 
process of ordering diabetic screenings was incorporated into the workflow and will continue 
after project completion.  
Implications for Patients   
The diabetic population has many compounding health concerns, with 40% of them 
developing kidney disease (NKF, 2016). Once a diabetic is diagnosed with kidney disease, a 
significant number will develop end-stage renal disease that requires dialysis or, worse, a kidney 
transplant (NKF, 2016).  Screening diabetic patients for kidney disease can identify kidney 
disease at its earliest stage and prevent future kidney damage (Gaitonde et al., 2017). Slowing the 
progression of kidney disease improves the care and outcomes of diabetic patients, allowing 
them to live a healthier, prolonged life. Recognizing kidney disease at the early stages gives 
providers vital information to alter treatment regimens for diabetic patients. Optimizing the plan 
of care for patients who are showing signs of kidney damage can lead to fewer hospitalizations 
and a significant decrease in the per capita cost of health care (Gaitonde et al., 2017). 
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 Implications for Nursing Practice  
Caring for patient’s health is essential to nursing practice. By increasing patient 
screenings for an illness that could be thwarted or prevented, the highest quality of care is being 
provided. Ordering kidney screenings is a simple act that has far-reaching nursing implications. 
When a positive microalbumin results, utilization of appropriate resources can be initiated. This 
often leads to patients being referred to specialists such as nephrologists, endocrinologists, or 
dieticians. These referrals often result in collaboration between health care disciplines and 
strengthen the care being provided to patients (Morley et al., 2017). This collaboration has been 
proven to increase patient participation and engagement in their care and leads to better patient 
outcomes.  
Furthermore, due to the education provided in this project, clinical staff have increased 
knowledge of the need to screen for kidney disease and the “why” behind the screening. This 
knowledge provides staff the confidence to educate diabetic patients about kidney disease. 
Communicating knowledge between clinical staff and patients generates trust with patients, 
which in turn increases patient’s adherence to strategies and medications to help them take 
control of their illness (Morley et al., 2017). Education is essential to nursing practice and the 
health of diabetic patients. The more the patient understands his or her disease process, the more 
likely that appropriate health actions are taken. 
It is of the utmost importance for nurses to take the lead in quality initiatives to improve 
patient outcomes (Altman et al., 2016). This project supports nurses in leading quality 
improvement initiatives and in collaboration by improving a work process, collaborating with 
others, and translating and applying research findings into practice. When nurses are involved in 
quality change, collaboration with interprofessional teams is enhanced, and better outcomes are 
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experienced. This project involved clinical teamwork in increasing the number of diabetic 
patients screened for chronic kidney disease (CKD) and relied heavily on collaboration between 
the site champion, project lead, lead physician, and the clinical staff. 
Impact for Healthcare System   
Kidney disease is a widespread disease that affects the health system on many levels. In 
2017 the total Medicare spending per person for those with kidney disease was $80,000 (CDC, 
2020). In 2016 Medicare spending for kidney failure patients cost $35 billion (University of 
California San Francisco(UCSF), 2019). Hemodialysis alone costs the Medicare system an 
average of $90,000 per patient, and spending for transplant patient care is $3.4 billion. Screening 
for kidney disease has financial benefits within the organization and promotes the health and 
wellness of the community at large. The healthcare system will have less cost burden of caring 
for kidney disease by identifying it early before it can progress and initiating crucial treatments 
(Gaitonde et al., 2017). Achieving the benchmark of over 95% for diabetic kidney screening also 
leads to financial reimbursement to this project organization through payer contract measures.  
  This project supports the Healthy People 2020 (2020a, 2020b) goals that address kidney 
screening in diabetic patients by increasing those who are screened for kidney disease, increasing 
persons with diabetes and CKD who receive medical evaluations with microalbuminuria, and 
reducing the proportion of the U.S. population with chronic kidney disease. Healthy People 2020 
aims to increase the proportion of persons with CKD who know they have impaired renal 
function. This project does this by directly screening patients for early identification of CKD. 
This project aligns with the Triple Aim Initiative by improving diabetic screening for kidney 
disease and enhancing patient experience by initiating needed treatments and leads to decreases 
in overall healthcare costs. 




The workflow changes that occurred to incorporate kidney screenings at this primary care 
clinic are self-sustaining. The newly developed process of ordering screenings by the medical 
assistants and providers will continue. The staff's knowledge of the updated protocol and when to 
order micro-albuminuria on diabetic patients has been enhanced and will continue to be utilized 
in the daily care of diabetic patients. The team has a better understanding of how the diabetic 
kidney screening metric is tracked, where to locate the EMR alerts regarding the screening, and 
how to identify if a screening is due. The kidney screening posters will remain with the staff in 
the pod areas and continue to remind them to screen long after project completion. The built-in 
EMR alert flags as a reminder for staff to screen for diabetic kidney disease. The knowledge 
gained by staff allows for peer education between new hires and current staff. 
The quality metric team is a part of the organization that impacts sustainability and will 
continue to track the metric and communicate information to the staff regarding the kidney 
screening metric. The team will continue to generate quarterly data reports that will provide 
updates on the status of health maintenance goals to staff.  
           The site champion at the organization, who is also the practice manager, assisted 
significantly with this project along with the lead primary care physician. They were responsible 
for encouraging providers in achieving the goals for financial reimbursements and improved 
patient care. The primary physician strives to meet patients' health goals and has a strong interest 
and commitment to the project's sustainability.  
Dissemination Plan 
On March 30, 2021, the project's overview and findings were presented in person to the 
project site champion and the site's clinical lead physician. A virtual poster presentation was 
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provided to the University College of Nursing faculty on April 6, 2021. At the completion of the 
project, the paper will be submitted to the University Scholarship Repository for public access. A 
project abstract will be submitted to the 2021 14th National Doctor of Nursing Practice 
Conference. This conference discusses quality care in nursing, and this project directly addresses 
improving quality care for diabetics in primary care. A paper submission along with an 
electronic poster will be submitted for review by May 1, 2021, for the International Conference 
on Clinical Nephrology and Diagnosis of Kidney Diseases held digitally on June 17, 2021. This 
DNP project directly addresses screening for nephropathy and diagnosis of kidney disease in the 
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Section VI. Conclusion 
Limitations 
 Several limitations were identified during the project. An initial limitation was being 
unable to meet with the entire staff at the project site to present an overview of the project and 
project details. Originally a meeting was scheduled at the project site that would take place 
during the lunch hour. However, due to the global COVID 19 pandemic, the project lead was 
asked to create an electronic format of the presentation and email it to staff instead. Being unable 
to present to all the staff in real-time led to minimal initial participation. The presentation was 
redistributed a week later with a small incentive to encourage participation.  
 Initially, the project lead had planned to schedule group meetings throughout the project 
to discuss progress, concerns, answer questions, etc. However, during the site visits, the project 
lead was unable to schedule times to meet with groups.  This was partly due to the site not 
allowing more than four individuals to meet at a time due to the COVID 19 pandemic. There 
were also limitations in staff availability related to provider's and staff’s busy schedules and time 
away from patient care. Due to these factors, staff was met with individually. 
A barrier identified during the project was with one provider and her panel of patients. 
This provider did not always adhere to the protocol with ordering the routine screenings, which 
included the nephropathy screening. This provider’s numbers for screening were significantly 
lower, which would bring the overall screening percentages down. This was identified during 
weeks five and six during the data collection review. . 
 Another barrier was related to data extraction. A third party was responsible for retrieving 
this data. At times, the system's electronic process for the extraction was inoperable. Another 
time the responsible party for data extraction was away from the office, and the staff member 
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who was covering was unsure how to send the data via email. After several phone calls and 
attempts, the data was successfully sent to the project lead for evaluation and only led to minor 
delays in interpreting data.  
Recommendations for Others 
Several recommendations for others are noted. It would be beneficial in the planning 
process to request data from the agency on the past screening rates for several months prior to 
implementation. This data would help strengthen the implementation process by helping the 
project lead know the providers and staff who were consistently ordering or not ordering the 
screenings. By having this information, follow-up could include visits with individualized 
education to address specific barriers and concerns. Offering incentives would provide staff 
encouragement to participating in the presentation. Scheduling a live webinar to present the 
project's material would be beneficial. This would engage staff in open discussions immediately 
following the presentation and could further increase participation. Rewarding staff with 
incentives as the organization achieves its goal can lead to staff satisfaction as well as 
compliance with screening. 
Although the project organization had a quality metric team, they were limited with 
staffing, and there were not enough team members to address each quality metric with each staff 
member. Consideration of additional staff within the quality metric department would help the 
organization ensure all quality metrics are met, including nephropathy screening.      
For evaluation, the data extraction was tedious because the project lead could not retrieve 
it without assistance. If a quality metrics team were relied upon to get data, a recommendation 
would include establishing a relationship with the individual who generates the reports. This 
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could be done by scheduling time with a quality team to review data extraction every several 
weeks to build that relationship.  
Recommendations Further Study 
There are many ways this project could be expanded or tailored to a specific 
organization. More research on the recommended interventions to treat abnormal 
microalbuminuria results could be integrated into this project. Additional research on how 
organizations could engage lab team members in increasing micro-albumin screenings could also 
be included. Considering ways to involve diabetic patients that were due for nephropathy 
screenings but not scheduled for an appointment could be an additional component to consider. 
This may include identifying ways to have patients come in for microalbumin urine screenings 
only without an office visit with the provider. 
Additional areas for further study would be identifying reasons why specific micro-
albuminuria screenings are not being obtained. For example, did the patient refuse? Did the lab 
forget to have the patient leave a urine sample? Did the provider order the screening but not 
direct the patient to the lab? Is the EMR alert not firing even when a diabetic kidney screening is 
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       Screening for Diabetic Nephropathy Protocol  
 
Diabetes Nephropathy Monitoring 
Definition:  The proportion of persons in the Diabetes Registry population, who have a 
documented nephropathy screening test or has been prescribed or is taking an ACE/ARB 




  Person's age is ≥ 18 as of the last day of the current measurement period. AND at least 
one of the following: 
 o  A problem of Diabetes Mellitus 
 o  TWO HbA1c level ≥ 6.5% 
 o  HbA1c level ≥ 9.0% 
 o  Estimated Average Glucose level ≥ 140 mg/dL, or ≥7.8 mmol/l 
 
  OR A start date for any Diabetic Medication (EXCLUDING Insulin, Metformin and 
Incretin Mimetic Medications) within the 18 months prior to the end of the current measurement 
period. 
 
   OR A diagnosis of Diabetes Mellitus Type 1 within the last 12 months AND  
 o      Fasting Plasma Glucose > 126 mg/dL during the current measurement period or the prior 
measurement period. 
 
  OR A diagnosis of Diabetes Mellitus Type 2 or Diabetes Mellitus Other within the last 
12 months AND at least one of the following: 
o   Fasting Plasma Glucose > 126 mg/dL. 
o  A start date for any Incretin Mimetic Medication within the 18 months prior to the end of 
the current measurement period. 
Exclusions: Gestational diabetics and those enrolled in hospice  
 
How to Meet the goal and screen for CKD:  
 
   Nephropathy Screening Test during the current measurement period. 
 
  OR person is prescribed ACE inhibitor/ARB therapy medication overlapping the current 
date, however this is not a substitute for screening for CKD.  
 
       Documentation of one of the following conditions in EMR in the measurement period will 
satisfy the benchmark and no need for screening will be needed: 
o       Diabetic Nephropathy 
o       End Stage Renal Disease 
o       Chronic Renal Failure 
o       Acute Renal Failure 
o       Proteinuria 
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o       Chronic Kidney Disease 
o       Glomerular Disorder 
o       Hypertensive Chronic Renal Disease 
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       Appendix D 












































         Data Collection Tool 
	
Week 1- Week 
12 





Number of patients 
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             Appendix H 
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  Appendix I  
 Microalbuminuria Screening Graph 
 
 














   Measures Evaluated  
   
                                  Weeks   1-2  3-4  5-6  7-8  9-10  11-12 
# of patients who have 
 CKD screening satisfied  42 57 66 53 85 74 
 # of patients eligible  
for micro-albuminuria     43 59 70 55 88 76 
% of patients who have  


























10 Lamination posters $25 
Printer Paper  $5 
Staff food Incentive  $15 
                       Total: $ 45 
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             DNP Essentials Mapping  
 
Doctor of Nursing Practice Essentials 





Competency – Analyzes and uses information to 
develop practice 
Competency -Integrates knowledge from humanities and 
science into context of nursing 
Competency -Translates research to improve practice 
Competency -Integrates research, theory, and practice to 
develop new approaches toward improved practice and 
outcomes 
• Information for this 
project was integrated 
from many different 
sources to reflect a well-
rounded understanding of 
the topic.  
  
• The literature review was 
done in many areas, 
including humanities and 
science. These findings 
led to the development of 
this project’s strategy, 
data collection tools, and 
review process to 
improve practice.  
  
• The information was 
translated into this project 
after critically reviewing 
studies. With this base 
and wealth of knowledge, 
the DNP student 
formulated 
implementation strategy 










Competency –Develops and evaluates practice based on 
science and integrates policy and humanities 
Competency –Assumes and ensures accountability for 
quality care and patient safety 
Competency -Demonstrates critical and reflective 
thinking 
Competency -Advocates for improved quality, access, 
and cost of health care; monitors costs and budgets 
Competency -Develops and implements innovations 
incorporating principles of change 
Competency - Effectively communicates practice 
knowledge in writing and orally to improve quality 
Competency - Develops and evaluates strategies to 
manage ethical dilemmas in patient care and within 
health care delivery systems 
 
The  
• This project 
communicated vital 
information regarding a 
quality care measure to 
staff. Each PDSA cycle 
completed was reflected 
on and critically analyzed 
to make changes to the 
implementation plan.  
 
• This project incorporated 
a change in the way the 
staff thought about and 
ordered urine screenings 
on diabetic patients.  
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• The project's poster, 
updated protocol, 
presentation, and site 
visits aided in 
incorporating the change 
to advocate for improved 
quality of care.  
 
• The overall act of 
screening for diabetic 
kidney disease early also 
affects the overall burden 
of cost. It reduces that 
cost on the health care 
system.  
 
• There is direct 
reimbursement to the 
project site through payer 
contract measures when 
the diabetic kidney 








Competency - Critically analyzes literature to determine 
best practices 
Competency - Implements evaluation processes to 
measure process and patient outcomes 
Competency - Designs and implements quality 
improvement strategies to promote safety, efficiency, and 
equitable quality care for patients 
Competency - Applies knowledge to develop practice 
guidelines 
Competency - Uses informatics to identify, analyze, and 
predict best practice and patient outcomes 




• An in-depth literature 
review was completed 
using a quantitative 
evidence pyramid. The 
review incorporated 
multiple resources and an 
in-depth evaluation 
process using the revised 
SQUIRE tool. A 
literature matrix 
hierarchy was used to sort 
the research and 
determine the most 
appropriate and strongest 
evidenced was used.  
 
• The knowledge gained 
from this review was 
incorporated into this 
project to create the tools 
used.  
 
• Collaboration took place 
between the DNP student, 
peers, the project advisor, 
and the project site 
champion.  












of Health Care 
Competency - Design/select and utilize software to 
analyze practice and consumer information systems that 
can improve the delivery & quality of care 
Competency -  Analyze and operationalize patient care 
technologies 
Competency - Evaluate technology regarding ethics, 
efficiency and accuracy 




• Technology was utilized 
to present the project’s 
presentation by use of 
PowerPoint, Excel, 
WebEx, Zoom & EMR. 
 
• Data was pulled 
electronically biweekly 
and sent to the DNP 
student for analysis.  
 
• Excel was used to 




• The technology in the 
EMR was incorporated 
into this project to 
improve compliance with 
the project's goal. 
 
•  Aspects of the EMR 
were reviewed with staff 











Competency- Analyzes health policy from the 
perspective of patients, nursing and other stakeholders 
Competency – Provides leadership in developing and 
implementing health policy 
Competency –Influences policymakers, formally and 
informally, in local and global settings 
Competency – Educates stakeholders regarding policy 
Competency – Advocates for nursing within the policy 
arena 
Competency- Participates in policy agendas that assist 
with finance, regulation and health care delivery 
Competency – Advocates for equitable and ethical 
health care 
• Aligns with Healthy People 
2020 goals by increases the 
total number of diabetics 
screened for kidney disease, 
increasing the number of 
diabetics aware they have 
kidney disease, increasing 
diabetics who are treated for 
kidney disease, and 
decreasing the overall 
healthcare burden of kidney 
disease  
 
• This project lowers the 
cost of healthcare by 
initiating early 
interventions for patients 
who have kidney disease 
 
• Increases the quality of 
care for diabetic patients 




• Decreases the amount of 
diabetic patient who will 











Competency- Uses effective collaboration and 
communication to develop and implement practice, 
policy, standards of care, and scholarship 
Competency – Provide leadership to interprofessional 
care teams 
Competency – Consult intraprofessionally and 
interprofessionally to develop systems of care in complex 
settings 
 
• Communication was at 
the core of this project. 
Without effective 
communication, the 
project's content would 
not be relayed to staff. 
 
• The project's tools were 
developed to address a 
gap in care and to 
increase the diabetic 
screenings for kidney 
disease.  
 
• Site visits by project lead 
were used to evaluate and 
implement change 
strategies. Collaboration 
with the DNP site 




the process of this 
project.  
 
• There were discussions 
between the quality 
metric staff and the DNP 
student to further 
understand the system 
and where the 
breakdown of ordering 








Competency- Integrates epidemiology, biostatistics, and 
data to facilitate individual and population health care 
delivery 
Competency – Synthesizes information & cultural 
competency to develop & use health promotion/disease 
prevention strategies to address gaps in care 
Competency – Evaluates and implements change 
strategies of models of health care delivery to improve 
quality and address diversity 
 
• Screening for diabetic 
kidney disease is a major 
part of health promotion. 
This project's main goal 
was to increase diabetic 
kidney screenings to 
catch kidney disease 
early on and protect the 
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diabetic population. This 
is a disease prevention 
strategy that directly 
promotes health.  
 
• There were different 
ways of going about this 
project, and different 
models and strategies 
were reviewed to 
formulate the best 
implementation process 
that could have the 
highest effectiveness on 
change.  
 
• The project's tools 
addressed a critical need 
in a health care system 
that affected a diverse 
group of patients 





Competency- Melds diversity & cultural sensitivity to 
conduct systematic assessment of health parameters in 
varied settings 
Competency – Design, implement & evaluate nursing 
interventions to promote quality 
Competency – Develop & maintain patient relationships 
Competency –Demonstrate advanced clinical judgment 
and systematic thoughts to improve patient outcomes 
Competency – Mentor and support fellow nurses 
Competency- Provide support for individuals and 
systems experiencing change and transitions 
Competency –Use systems analysis to evaluate practice 
efficiency, care delivery, fiscal responsibility, ethical 
responsibility, and quality outcomes measures 
 
• Creating and cultivating 
interprofessional 
relationships led to 
increased compliance 
with the goals.  
 
• Demonstrated support to 
fellow clinical staff 
during the four site visits. 
Mentorship took place 
between the DNP student 
and the staff as well as 
between the project 
adviser and project lead.  
 
• Provided support to the 
clinic to help increase this 
screening goal on many 
levels.  
 
• The PDSA was used to 
analyze and evaluate the 
nursing interventions. 
This allowed for the DNP 
student to critically 
evaluate practice and 
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make clinical judgments to 
improve and promote 
quality in health care. 
 
 
 
 
 
 
 
 
 
